feed,title,long_url,short_url
Benzinga,"CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst",https://benzinga.com/analyst-ratings/analyst-color/24/02/37102983/cymabay-therapeutics-deal-may-not-be-needle-moving-for-100b-valued-gilead-but-acqui,https://da.gd/iNkllh
